2′-MOE	2′-O-methoxyethyl
2′-OMe	2′-O-methyl
6-FAM™	6-Carboxyfluorescein
Ago-2	protein argonaute-2
ApoB	Apolipoprotein B
ART	antiretroviral therapy
ASO	antisense oligonucleotide
Bcl-2	Apoptosis regulator Bcl-2
CA	capsid
CCR4–NOT	carbon catabolite repressor 4- negative on TATA
D3	splice donor 3
DCP1/2	mRNA-decapping enzyme 1/2
DMD	Duchenne muscular dystrophy
ERK2	mitogen-activated protein kinase 1
ESEtat	exonic splicing enhancer tat
ExJ 3/4	exon junction exon3/exon4
FDA	U.S. Food and Drug Administration
Gapmer	LNAs at the 5′- and 3′ end and a DNA strand in the center of the ASO
GAR	guanosine-adenosine-rich exonic splicing enhancer
GI3-2	second G-run within HIV-1 intron 3
GW-182	glycine-tryptophan protein of 182 kDa
GW-body	cytoplasmic foci containing enzymes involved in RNA degradation and translational repression
HCV	hepatitis C virus
HIV-1	human immunodeficiency virus type 1
hnRNP	Heterogeneous nuclear ribonucleoproteins
IL-2	Interleukin-2
LNA	Locked nucleic acid
miRNA	microRNA
Mixmer	mixed combination of LNA and DNA residues within the ASO
PAZ domain	Piwi/Argonaute/Zwille domain
PBMC	peripheral blood mononuclear cell
PMO	phosphorodiamidate morpholinos
PS	phosphorothioate
RNAi	RNA interference
RRE	Rev responsive element
SA3	splice acceptor 3
SIRC	stress-induced response complex
siRNA	small interfering RNA
SMA	spinal muscular atrophy
SR	serine and arginine-rich protein
SRE	splicing regulatory element
SRSF6	serine/arginine-rich splicing factor 6
SSO	splice-switching oligonucleotide
TAR	trans-activation response element
U1 snRNA	U1 small nuclear ribonucleic acid
WHO	World Health Organization
XRN1	5’-3’ exoribonuclease 1